Gilead Sciences has paid $80m to join Astrazeneca, Sanofi and Novartis in chasing TGF-beta antibodies, securing an option to license three projects in a deal with Scholar Rock. The big biotech group will have rights to three preclinical projects: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localised to extracellular matrix, and a third TGFβ discovery program. While the two companies were not specific about the conditions in which any of the projects might be advanced, Gilead’s interest in Nash makes this an obvious target – though Gilead’s fibrotic diseases team is already occupied with trials of selonsertib, GS-9674 and GS-0976. In any case, Scholar Rock has yet to discover specific antibodies and nominate candidates, a task for which it will be responsible, after which Gilead will have an option to license the assets and take over development. Scholar Rock also has a deal with Johnson & Johnson for a TGFβ1 asset in oncology.
|Select TGF-beta MAbs in development|
|Phase I||GC1008||AstraZeneca/Sanofi||Osteogenesis imperfecta|
|Preclinical||SB-001||Solid Biosciences||Duchenne muscular dystrophy|